Abstract

Since the publication of the Society for Immunotherapy of Cancer’s (SITC) original cancer immunotherapy biomarkers resource document, there have been remarkable breakthroughs in cancer immunotherapy, in particular the development and...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Jianda Yuan ... Lisa H Butterfield
Journal for ImmunoTherapy of Cancer | VOL. 4
Jianda Yuan, et. al.Jianda Yuan ... Lisa H Butterfield
19 Jan 2016
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A Davis ... Vaibhav G Patel
Journal for ImmunoTherapy of Cancer | VOL. 7
Andrew A Davis, et. al.Andrew A Davis ... Vaibhav G Patel
26 Oct 2019
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer
Andrew Zloza ... Marcus W Bosenberg
Journal for ImmunoTherapy of Cancer | VOL. 5
Andrew Zloza, et. al.Andrew Zloza ... Marcus W Bosenberg
19 Sep 2017
Immunotherapy in kidney cancer: the past, present, and future.
Hans Hammers
Current Opinion in Urology | VOL. 26
Hans HammersHans Hammers
01 Nov 2016
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
EphA3 CAR T cells are effective against glioblastoma in preclinical models
Paulo Martins ... Rajiv Khanna
Journal for ImmunoTherapy of Cancer | VOL. 12
Paulo Martins, et. al.Paulo Martins ... Rajiv Khanna
07 Aug 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Michael Schenker ... Massimo Di Nicola
Journal for ImmunoTherapy of Cancer | VOL. 12
Michael Schenker, et. al.Michael Schenker ... Massimo Di Nicola
06 Aug 2024
Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer
Zixiang Wang ... Baoxia Cui
Journal for ImmunoTherapy of Cancer | VOL. 12
Zixiang Wang, et. al.Zixiang Wang ... Baoxia Cui
06 Aug 2024
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
Diwakar Davar ... Allison Naumovski
Journal for ImmunoTherapy of Cancer | VOL. 12
Diwakar Davar, et. al.Diwakar Davar ... Allison Naumovski
03 Aug 2024
View more papers